Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA


Novartis announced today that the US Food and Drug Administration has approved Cosentyx for two new indications - the treatment of adult patients with active ankylosing spondylitis and active psoriatic arthritis . AS and PsA are both life-long, painful and debilitating inflammatory diseases that affect the joints and/or spine.



from Biotech News